Trials / Terminated
TerminatedNCT07030868
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
A Phase 2, Parallel-Group, Double-Blind 4-arm Study to Investigate the Effects of Treatment With LY3549492 Tablets Compared With Placebo in an Obese or Overweight Population With Type-2 Diabetes (T2D)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight with type 2 diabetes. Participation in the study will last about 11 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY6249492 | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2025-06-19
- Primary completion
- 2025-07-29
- Completion
- 2025-07-29
- First posted
- 2025-06-22
- Last updated
- 2025-08-29
Locations
42 sites across 2 countries: United States, Argentina
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07030868. Inclusion in this directory is not an endorsement.